Company reportsPresentationsAnnouncementsCurrently selectedAnnual General MeetingFinancial calendarCorporate governanceData of sharesConferences, roadshowsAnalystsContact Announcements Annual General Meeting 2020 - Documents04/06/20Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.03/31/20Budapest, Hungary and Basel, Switzerland – 31 March 2020 – Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Gedeon Richter Plc., a major pharmaceutical company in Central Eastern Europe focused on women's health, today announced that they have entered into an exclusive license agreement for Gedeon Richter to commercialize relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia, and New Zealand. Under the agreement, Myovant will receive an upfront payment of $40 million and is eligible to receive up to $40 million in regulatory milestones and $107.5 million in sales related milestones, and tiered royalties on net sales following regulatory approval. Myovant retains all rights to relugolix combination tablet in the U.S., as well as rights to relugolix in other therapeutic areas outside of women's health. Composition of share capital and voting rights03/31/20Annual General Meeting 2020 - Invitation 03/27/20The Chemical Works of Gedeon Richter Plc.(Richter Gedeon Vegyészeti Gyár Nyilvánosan Működő Rt.)(H-1103 Budapest, Gyömrői út 19-21.) hereby informs its honorable shareholders that due to the situation caused by the coronavirus epidemic (Covid-19) and having regard to applicable laws (in particular Section 4 of Government Decree No. 46/2020. (III.16.)) the Company sees no possibility to hold its annual general meeting previously set to the day of April 28, 2020 in the corporate action timetable for year 2020, in person in accordance with the regulations of the Company's Statutes. Annual General Meeting 2020 - Remuneration statement03/27/20 Gedeon Richter Plc. based upon Section 11.6 of the Company's Statutes hereby announce, per member and described by virtue of the remuneration, all in cash and other (non cash) allowances given to the Members of the Board of Directors and of the Supervisory Board with reference to their such position in 2019: Archive
Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.03/31/20Budapest, Hungary and Basel, Switzerland – 31 March 2020 – Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, and Gedeon Richter Plc., a major pharmaceutical company in Central Eastern Europe focused on women's health, today announced that they have entered into an exclusive license agreement for Gedeon Richter to commercialize relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for uterine fibroids and endometriosis in Europe, the Commonwealth of Independent States including Russia, Latin America, Australia, and New Zealand. Under the agreement, Myovant will receive an upfront payment of $40 million and is eligible to receive up to $40 million in regulatory milestones and $107.5 million in sales related milestones, and tiered royalties on net sales following regulatory approval. Myovant retains all rights to relugolix combination tablet in the U.S., as well as rights to relugolix in other therapeutic areas outside of women's health.
Annual General Meeting 2020 - Invitation 03/27/20The Chemical Works of Gedeon Richter Plc.(Richter Gedeon Vegyészeti Gyár Nyilvánosan Működő Rt.)(H-1103 Budapest, Gyömrői út 19-21.) hereby informs its honorable shareholders that due to the situation caused by the coronavirus epidemic (Covid-19) and having regard to applicable laws (in particular Section 4 of Government Decree No. 46/2020. (III.16.)) the Company sees no possibility to hold its annual general meeting previously set to the day of April 28, 2020 in the corporate action timetable for year 2020, in person in accordance with the regulations of the Company's Statutes.
Annual General Meeting 2020 - Remuneration statement03/27/20 Gedeon Richter Plc. based upon Section 11.6 of the Company's Statutes hereby announce, per member and described by virtue of the remuneration, all in cash and other (non cash) allowances given to the Members of the Board of Directors and of the Supervisory Board with reference to their such position in 2019:
